|
27 Sep 2021 |
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
|
|
27 Sep 2021 |
Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease
|
|
23 Sep 2021 |
Lion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma
|
|
22 Sep 2021 |
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
|
|
20 Sep 2021 |
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial
|
|
18 Sep 2021 |
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
|
|
16 Sep 2021 |
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
|
|
15 Sep 2021 |
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
|
|
15 Sep 2021 |
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
|
|
15 Sep 2021 |
Neurogene Announces FDA Clearance of IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease
|
|
15 Sep 2021 |
T-Cure Bioscience Announces U.S. FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T Against Multiple Solid Tumors
|
|
15 Sep 2021 |
GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia
|
|
15 Sep 2021 |
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
|
|
15 Sep 2021 |
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
|
|
15 Sep 2021 |
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
|
|
11 Sep 2021 |
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
|
|
08 Sep 2021 |
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
|
|
08 Sep 2021 |
Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001
|
|
07 Sep 2021 |
TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases
|
|
07 Sep 2021 |
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
|
|
06 Sep 2021 |
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
|
|
06 Sep 2021 |
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
|
|
06 Sep 2021 |
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
|
|
03 Sep 2021 |
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
|
|
02 Sep 2021 |
Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR® Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer
|
